ERBB2 and neoplasm: However, increasing evidence points to significant intertumoral heterogeneity in such cases, including discordant expression of hormone receptors, HER2, and proliferation indices between synchronous tumor foci, which may lead to treatment undertreatment or overtreatment if not fully characterized [4,5].